CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody

Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas

(2009) H.-P. Gerber et al.   BLOOD

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

(2008) R. Lapalombella et al.   BLOOD

Colocalization of the IL-12 receptor and Fc RIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon- 

(2008) S. V. Kondadasula et al.   BLOOD

The impact of Fc engineering on an anti-CD19 antibody: increased Fc  receptor affinity enhances B-cell clearing in nonhuman primates

(2008) J. Zalevsky et al.   BLOOD

Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

(2008) H. M. Horton et al.   CANCER RESEARCH

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

(2008) L. Wu et al.   CLINICAL CANCER RESEARCH

Functions of natural killer cells

(2008) Eric Vivier et al.   NATURE IMMUNOLOGY